Renalytix Plc (RNLXY OTCQB) stock market data APIs
$0.1749
0.01(5.7%)
as of December 12, 2025
Try our APIs with
free plan!
Renalytix Plc Financial Data Overview
Price chart is built with
Anychart
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.
Prev. Close
0.1749
Open
0.1836
High
0.1849
Low
0.1744
52 wk Range
0.125-0.324
Market Cap
38 239 K
Shares Outstanding
219 M
Revenue
3 000 K
EPS
0
Beta
1.842
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Renalytix Plc data using free add-ons & libraries
Get Renalytix Plc Fundamental Data
Renalytix Plc Fundamental data includes:
- Net Revenue: 3 000 K
- EBITDA: -16 800 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: -0.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Renalytix Plc News
New
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK, Sept. 15, ...
MVP Health Care partners with Renalytix for kidney disease risk testing
NEW YORK - MVP Health Care and Renalytix plc (LSE:RENX) (OTCQB:RNLXY) announced Thursday a partnership to provide kidneyintelX.dkd testing to MVP’s 700,000 members in the northeastern United States....
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
